June 4, 2020 / 1:36 PM / 2 months ago

BRIEF-DelMar Pharmaceuticals' VAL-083 Selected To Participate In Global Coalition For Adaptive Research's GBM AGILE Pivotal Study

June 4 (Reuters) - DelMar Pharmaceuticals Inc:

* GLOBAL COALITION FOR ADAPTIVE RESEARCH (GCAR) SELECTS DELMAR PHARMACEUTICALS’ VAL-083 TO PARTICIPATE IN THE GBM AGILE PIVOTAL STUDY, AN ADAPTIVE CLINICAL TRIAL PLATFORM IN GLIOBLASTOMA MULTIFORME Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below